Department of Medicine III, University of Aachen (RWTH), Pauwelsstraße 30, 52074 Aachen, Germany.
Hepatobiliary Surg Nutr. 2015 Feb;4(1):24-33. doi: 10.3978/j.issn.2304-3881.2015.01.05.
Liver cirrhosis represents the end stage of most chronic inflammatory liver diseases and is a major global health burden. Despite the enormous relevance of cirrhotic disease, pharmacological strategies for prevention or treatment of hepatic fibrosis are still limited, underlining the need to establish a better understanding of the molecular mechanisms underlying the pathogenesis of hepatic cirrhosis. Recently, miRNAs have emerged as a new class of RNAs that do not withhold the information to encode for proteins but regulate whole gene expression networks during different physiological and pathological processes. Various authors demonstrated that miRNA species are functionally involved in the regulation of chronic liver damage and development of liver cirrhosis in inflamed livers. Moreover, circulating miRNA patterns were suggested to serve as blood-based biomarkers indicating liver injury and progression to hepatic cirrhosis and cancer. Here we summarize current findings on a potential role of miRNAs in the cascade leading from liver inflammation to liver fibrosis and finally hepatocellular carcinoma. We compare data from animal models with findings on miRNAs dysregulated in human patients and finally highlight a potential use of miRNAs as biomarkers for liver injury, fibrosis and cancer.
肝硬化是大多数慢性炎症性肝病的终末期阶段,是全球主要的健康负担之一。尽管肝硬化疾病具有重要意义,但预防或治疗肝纤维化的药物治疗策略仍然有限,这突显了需要更好地了解肝纤维化发病机制的分子机制。最近,miRNA 作为一类新的 RNA 出现,它们不包含编码蛋白质的信息,而是在不同的生理和病理过程中调节整个基因表达网络。许多作者证明,miRNA 物种在调节慢性肝损伤和炎症性肝脏中肝硬化的发展中具有功能作用。此外,循环 miRNA 模式被认为可以作为基于血液的生物标志物,指示肝损伤和向肝硬化和肝癌的进展。在这里,我们总结了 miRNA 在从肝炎症到肝纤维化最终到肝细胞癌的级联反应中可能发挥作用的最新发现。我们将动物模型中的数据与人类患者中失调的 miRNA 研究结果进行了比较,最后强调了 miRNA 作为肝损伤、纤维化和癌症生物标志物的潜在用途。